It is estimated that CagriSema could hit the market by late 2025 or early 2026, pending the outcome of Novo Nordisk s phase 3 trials, expected later this year and in early 2025
Relationships vs Efficiency 02:08:46 Technology, Relationships, Frustration Tolerance, Gratification 02:15:18 Slowing Down, Phones, Frustration, Capability 02:21:42 Immediate Gratification, Effort & Struggle, Dopamine 02:29:25 Confidence, Board Games, Parental Modeling 02:34:04 Ultra-Performers & Pressure, Emptiness 02:41:29 Trying Things, Unlived Dreams, Frustration Tolerance, Tool: Learning Space 02:51:08 Learning & Building Frustration Tolerance, Tantrums
Side Effects and Precautions Long-term glutathione supplementation may lead to lower zinc levels
For research use only not medical guidance
In practice, exogenous follistatin delivery is not currently clinically feasible the molecule doesn't survive oral administration, injectable forms have short half-lives, and there is no approved delivery system